STAAR Surgical Reports 24% Revenue Drop, Posts $80.4M Net Loss in 2025 10-K
summarizeSummary
STAAR Surgical reported a significant downturn in its fiscal year 2025 results, with net sales declining 23.7% year-over-year to $239.4 million and the company posting a net loss of $80.4 million, or $(3.26) per share. This substantial revenue drop was primarily attributed to weaker demand in China and distributor inventory normalization. The material underperformance, detailed in the annual 10-K filing, indicates significant operational headwinds and will likely lead to negative investor sentiment and pressure on the stock. Traders will be closely watching for signs of stabilization in the China market and the effectiveness of the company's stated strategic focus for 2026, which includes targeted investments and continued innovation to accelerate ICL adoption.
At the time of this announcement, STAA was trading at $17.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $941.1M. The 52-week trading range was $14.69 to $30.81. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.